Heart monitor reveals hidden damage from cancer radiation
NCT ID NCT04183218
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looked at 24 people with lung or esophageal cancer who received radiation or chemo-radiation near the heart. Participants wore a small heart monitor to catch any heart changes that might otherwise go unnoticed. The goal was to see how often heart problems occur after such treatment, so doctors can manage them earlier.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors detect and treat heart problems early in cancer patients receiving radiation near the heart.
- What could go wrong
- This is a small, completed observational study with only 24 participants, so results may not apply to everyone. It does not test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
24 people
The number who actually took part.
- Started
-
Sep 2019
- Finished
-
May 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Non-metastatic, non-recurrent lung and esophageal cancer patients who are receiving thoracic radiotherapy
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \>= 18 years * Planned standard of care curative thoracic RT or CRT with anticipated heart V40 \> 20 cc (At least 20 cc of the heart should receive a dose of 40 gray \[Gy\] or higher) * Able to follow-up at all specified standard of care time-points * Patients can receive treatment as part of the standard of care or in a different study * Receiving radiation treatment to an area close to the heart, for example gastroesophageal junction cancer, hilar lung cancer, or mainstem bronchus lung cancer * Any type of systemic therapy or surgery before during or after radiation is acceptable * Prior radiation to other areas is acceptable * Planned radiation doses equal or higher than 40 Gy Exclusion Criteria: * Metastatic disease * Recurrent disease * Patient receiving radiation prescription doses lower than 40 Gy * No prior radiation that included any part of the heart is acceptable * No thoracic re-irradiation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Clinical stage 0 esophageal adenocarcinoma ajcc V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood proteins may predict who beats esophageal cancer with chemoradiation
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers
- Can a direct hit to tumors make immunotherapy work better?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Can a vaccine stop GI cancers from returning?
- Can a guided missile for chemo hit tumors harder and spare healthy tissue?